Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kidney Transplant Rejection Clear all
Not listed No phase listed Observational

TruGraf and TRAC In Pediatrics Study

NCT05335538
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Patients monitored with TruGraf and TRAC testing
Diagnostic Test
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
1 Year to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Birmingham, Alabama • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Jul 23, 2026, 2:45 AM EDT
Enrolling by invitation Phase 2 Interventional

Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT05285878
View directory record Official record
Conditions
Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection, Kidney Transplant Failure, Kidney Failure, Chronic, Graft Rejection
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jul 23, 2026, 2:45 AM EDT
Active, not recruiting No phase listed Observational

The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)

NCT04091984
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Prospera
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

NCT00089947
View directory record Official record
Conditions
Renal Transplantation, Graft Rejection
Interventions
Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

NCT03380377
View directory record Official record
Conditions
Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 23, 2026, 2:45 AM EDT
Recruiting No phase listed Observational

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

NCT01644903
View directory record Official record
Conditions
Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 1 Interventional

Tolerance by Engaging Antigen During Cellular Homeostasis

NCT03504241
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
Interventions
Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept, sirolimus, mycophenolate mofetil, mycophenolate acid, prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 23, 2026, 2:45 AM EDT
Terminated Not applicable Interventional

Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation

NCT00579592
View directory record Official record
Conditions
Acute Rejection, Renal Transplantation
Interventions
Campath-1H, rituximab, myfortic
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Extended Release Tacrolimus vs. Twice-Daily Tacrolimus

NCT03289650
View directory record Official record
Conditions
End Stage Renal Disease, Rejection of Renal Transplant
Interventions
Tacrolimus, Tacrolimus Extended Release Oral Tablet [Envarsus]
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 4 Interventional Results available

Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant

NCT00118742
View directory record Official record
Conditions
Liver Transplantation
Interventions
mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine, Sirolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 74 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2010 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection

NCT02936479
View directory record Official record
Conditions
Antibody Mediated Rejection of Kidney Transplant
Interventions
C1-INH (Berinert)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Jul 23, 2026, 2:45 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Identification of Donor Specific B Cells and Antibody Mediated Rejection

NCT02133248
View directory record Official record
Conditions
Sensitized Kidney Transplant Recipients
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 4 Interventional Results available

Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

NCT00895583
View directory record Official record
Conditions
Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
Interventions
Tacrolimus, Sirolimus
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
25
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection

NCT00117689
View directory record Official record
Conditions
Liver Dysfunction, Rejection, Transplant, Transplantation, Liver
Interventions
Thymoglobulin, Corticosteroid, Tacrolimus, Mycophenolate Mofetil
Biological · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Jul 23, 2026, 2:45 AM EDT
Not yet recruiting Phase 2 Interventional

(TNX-1500) in Kidney Transplant Recipients

NCT07204080
View directory record Official record
Conditions
Kidney Transplant, Kidney Transplant Failure and Rejection, Immunosuppression, Immunosuppression After Kidney Transplantation
Interventions
TNX-1500, Kidney Transplant
Drug · Procedure
Lead sponsor
Ayman Al Jurdi, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 2:45 AM EDT
Completed No phase listed Observational

The TOGETHER Project - Kidney

NCT03873623
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection

NCT00006178
View directory record Official record
Conditions
Kidney Failure
Interventions
Sirolimus, Thymoglobulin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Jul 23, 2026, 2:45 AM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

NCT00275509
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 4 Interventional

A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

NCT00363116
View directory record Official record
Conditions
Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Interventions
Daclizumab
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
23
States / cities
Davis, California • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Jul 23, 2026, 2:45 AM EDT
Not listed Phase 4 Interventional

Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)

NCT04849533
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Belatacept, Everolimus, mycophenolate mofetil, corticosteroids, rabbit antithymocyte globulin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Jul 23, 2026, 2:45 AM EDT
Terminated Phase 4 Interventional Results available

Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation

NCT02974686
View directory record Official record
Conditions
Kidney Transplant Rejection, Gastrointestinal Disorder, Functional
Interventions
Everolimus, Mycophenolic Acid
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Jul 23, 2026, 2:45 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance

NCT04566055
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AlloSure
Device
Lead sponsor
CareDx
Industry
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Aurora, Colorado • Tampa, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 4 Interventional Results available

Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)

NCT01953120
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Belatacept
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Jul 23, 2026, 2:45 AM EDT